Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Missing In Action: FDA, Sponsors Quiet About Pending Applications

Executive Summary

Approval of Sandoz's Zarxio aside, dearth of advisory committee meeting announcements and sponsors' reluctance to discuss status of 351(k) filings suggests regulatory road has not been smooth for some early biosimilar candidates.

Advertisement

Related Content

Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel